Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

University of Calgary

$135,000.00

Brain-specific enzyme cholesterol 24-hydroxylase (Cyp46A1) as a novel therapeutic target in human prion diseases

FY 2020-21

Summary
Prion diseases are infectious and fatal neurodegenerative disorders that affect humans and animals. Creutzfeldt-Jakob disease (CJD) is the most common human prion disease. Animal prion diseases include scrapie in sheep/goat and mad cow disease which has been transmitted to humans from cattle, as well as chronic wasting disease, a contagious prion disease in deer, moose and elk. Currently, there is no treatment available for prion diseases, therefore, in this study we will apply a novel strategy to treat those deadly diseases. Brain synthesizes cholesterol which is a major component of brain cells; however, its excess amount is harmful as it cannot exit the brain. In prion diseases, we know that cholesterol is required for the formation of prions and that the buildup of prions further increases cholesterol levels in the brain, facilitating prion formation. Therefore, regulating brain cholesterol during prion infection could prevent prion disease The main pathway for brain cholesterol elimination is achieved by the brain-specific enzyme, cholesterol 24-hydroxylase (Cyp46A1). Cyp46A1 converts cholesterol into 24(S)-hydroxycholesterol, a molecule that exits the brain. It is of utmost importance to determine the role of Cyp46A1 in prion diseases. We have collected preliminary data that indicate for the first time that the brains of prion-infected mice and CJD-patients have reduced Cyp46A1 levels This project will be the first to determine the therapeutic efficacy of the Cyp46A1 activator, Efavirenz (EFV) in prion diseases. EFV is an FDA-approved drug which reaches the brain and is currently used for the treatment of HIV patients. Our goal is to test if this drug could be repurposed for treatment of prion diseases using mechanistic approaches of human prion models. Thus, Cyp46A1 would be a novel target, and its activation through repurposed medications such as EFV is a valuable approach for the treatment of prion diseases which will benefit Canadians and global health
Program
CIHR Fellowship
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
440680
Name
Ali Tahir
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Brain-specific enzyme cholesterol 24-hydroxylase (Cyp46A1) as a novel therapeutic target in human prion diseases
Programtype2
Fellowship Programs
Orgnameinp2
University of Calgary
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Brain Cholesterol Metabolism; Cellular Models Of Prion Diseases; Cholesterol 24-Hydroxylase (Cyp46a1); Cyp46a1 Activator (Efavirenz); Fda-Approved Repurposed Drug (Efavirenz); Human Prion Diseases; Mouse Models Of Human Prion Diseases; Neurodegenerative Diseases; Neurosciences; Treatment Of Human Prion Diseases
Abstract
Prion diseases are infectious and fatal neurodegenerative disorders that affect humans and animals. Creutzfeldt-Jakob disease (CJD) is the most common human prion disease. Animal prion diseases include scrapie in sheep/goat and mad cow disease which has been transmitted to humans from cattle, as well as chronic wasting disease, a contagious prion disease in deer, moose and elk. Currently, there is no treatment available for prion diseases, therefore, in this study we will apply a novel strategy to treat those deadly diseases. Brain synthesizes cholesterol which is a major component of brain cells; however, its excess amount is harmful as it cannot exit the brain. In prion diseases, we know that cholesterol is required for the formation of prions and that the buildup of prions further increases cholesterol levels in the brain, facilitating prion formation. Therefore, regulating brain cholesterol during prion infection could prevent prion disease The main pathway for brain cholesterol elimination is achieved by the brain-specific enzyme, cholesterol 24-hydroxylase (Cyp46A1). Cyp46A1 converts cholesterol into 24(S)-hydroxycholesterol, a molecule that exits the brain. It is of utmost importance to determine the role of Cyp46A1 in prion diseases. We have collected preliminary data that indicate for the first time that the brains of prion-infected mice and CJD-patients have reduced Cyp46A1 levels This project will be the first to determine the therapeutic efficacy of the Cyp46A1 activator, Efavirenz (EFV) in prion diseases. EFV is an FDA-approved drug which reaches the brain and is currently used for the treatment of HIV patients. Our goal is to test if this drug could be repurposed for treatment of prion diseases using mechanistic approaches of human prion models. Thus, Cyp46A1 would be a novel target, and its activation through repurposed medications such as EFV is a valuable approach for the treatment of prion diseases which will benefit Canadians and global health
Competitiondate
202012
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Ali, Tahir
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~
University of Calgary - $135,000 Grant (2020-21) | Canada Spends